Prostate cancer is the most common cancer among men in the United States after non-melanoma skin cancer, and is the third leading cause of cancer-related deaths. Prostate cancer is often a slow-growing cancer and is typically detected early making it easier to treat. Currently, CyberKnife is most frequently used by itself for patients with early stage prostate cancer confined to the prostate.
- Delivers radiation directly to the tumor
- Minimizes exposure to surrounding healthy tissue
- Continually checks and compensates for any movement you make during treatments, ensuring accuracy
- Patient can breathe normally during the treatment sessions
- Achieves surgical-like outcomes, non-invasively
- Requires no recovery time. Most treatments are done on an outpatient basis
- Reduces pain
- Requires only mild sedation
Prostate cancer can be a challenge for physicians to treat since the prostate moves unpredictably as air passes through the rectum and as the bladder empties and fills. CyberKnife treatment can overcome this challenge by continually checking and compensating for any movements during treatment. This allows the radiation to zero in on the tumor and help reduce harming the healthy tissue. During the treatment a patient can lie down and breathe normally while the doctor performs the treatment. As a result, CyberKnife is more comfortable for patients and treatments can be completed in one to five sessions.
CyberKnife treatments are typically performed on an outpatient basis over a period of one to five days, requiring no overnight hospital stays. Most patients experience minimal to no side effects with a quick recovery time.